Wednesday, November 05, 2025 The LY16 (LYSARC RELEVANCE) phase III open-label randomized study to compare the efficacy and safety of rituximab plus lenalidomide (CC-5013) versus rituximab plus chemotherapy followed by rituximab in subjects with previously untreated follicular lymphoma trial is permanently closed. The letter of permanent trial closure/termination can be found in the members' area of the CCTG webpage under "Toolbox-Reports-Trial Closure" here: https://www.ctg.queensu.ca/trials/permanent_closure/permanent-trial-closureThe purpose of this study is to find out if lenalidomide when given along with rituximab can help to control the disease and also increase the length of your response (complete or partial response) compared to the standard of care rituximab chemotherapy treatment.Primary PublicationMorschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GARituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma New England Journal of Medicine:379(10):934 -947,2018
